The scientific community must take a strong and active stand against vaccine revisionism — the false narrative that there is insufficient evidence to support the safety and efficacy of vaccines.

Johanna Joyce describes how disrupting tumor-associated macrophages showed the importance of the tumor microenvironment in treating cancer.

The latest brain–computer interfaces in pre-clinical testing receive — and send — signals, training the brains of participants.

This Review summarizes recent and compelling examples of microbiome-based interventions that are ripe for clinical adoption while also discussing the challenges and opportunities facing the field.

The authors found, after analyzing 10,960 individuals from 9 multiancestry biobanks across 6 countries, that genetic factors previously associated with BMI have limited impact on GLP-1 receptor agonist-induced weight loss.

In a patient with treatment-refractory idiopathic inflammatory myositis, re-infusion of CD19 CAR-T cells following disease relapse led to the development of anti-CD19 CAR T cells and no clinical improvement, with drug-free remission induced again after treatment with BCMA CAR-T cells

A meta-prediction framework integrating polygenic risk scores spanning multiple conditions and nongenetic factors, such as laboratory tests and baseline diagnoses, had superior performance in predicting the 10-year risk of coronary artery disease compared with standard clinical scores and previously developed polygenic risk scores.

In the OptiTROP-Breast01 phase 3 trial, patients with metastatic triple-negative breast cancer who received the TROP2-targeted antibody–drug conjugate sacituzumab tirumotecan experienced longer progression-free survival than patients treated with chemotherapy.

Intracytoplasmic sperm injection, usually reserved for cases of male infertility, was found to be nonsuperior to conventional in vitro fertilization in couples without male infertility concerns.

In a phase 1/2 trial in patients with advanced non-small-cell lung cancer (NSCLC), followed by a phase 2 trial in an EGFR-mutant selected population, treatment with the TROP2-targeting antibody–drug conjugate sacituzumab tirumotecan led to encouraging clinical response rates, especially in patients with EGFR-mutant NSCLC, which was supported by mechanistic data.

Despite a negative primary outcome, a trial of gantenerumab showed a clinically meaningful slowing of disease onset in asymptomatic people who were treated for the longest duration.

The latest brain–computer interfaces in pre-clinical testing receive — and send — signals, training the brains of participants.

Johanna Joyce describes how disrupting tumor-associated macrophages showed the importance of the tumor microenvironment in treating cancer.

The first pig liver to be transplanted into a human (in this case, a brain-dead recipient) showed sustained function without rejection — marking another step toward xenotransplantation as a viable approach to addressing the organ-shortage crisis.

The World Health Organization’s inaugural Investment Round aims to instill stability in the face of global health headwinds and a US exit.